Attached files

file filename
EX-10.7 - EXHIBIT 10.7 - SYNERGY PHARMACEUTICALS, INC.troyhamiltonemploymentagre.htm
10-K - 10-K - SYNERGY PHARMACEUTICALS, INC.sgyp-123117x10k.htm
EX-32.2 - EXHIBIT 32.2 - SYNERGY PHARMACEUTICALS, INC.sgyp-ex322x123117x10k.htm
EX-32.1 - EXHIBIT 32.1 - SYNERGY PHARMACEUTICALS, INC.sgyp-ex321x123117x10k.htm
EX-31.2 - EXHIBIT 31.2 - SYNERGY PHARMACEUTICALS, INC.sgyp-ex312x123117x10k.htm
EX-31.1 - EXHIBIT 31.1 - SYNERGY PHARMACEUTICALS, INC.sgyp-ex311x123117x10k.htm
EX-21 - EXHIBIT 21 - SYNERGY PHARMACEUTICALS, INC.exhibit21.htm
EX-10.14 - EXHIBIT 10.14 - SYNERGY PHARMACEUTICALS, INC.amendmenttotermloanagreeme.htm
EX-10.13 - EXHIBIT 10.13 - SYNERGY PHARMACEUTICALS, INC.garyjacobemploymentagreeme.htm
Consent of Independent Registered Public Accounting Firm

Synergy Pharmaceuticals Inc.
New York, New York
We hereby consent to the incorporation by reference in the Registration Statements on Form S­3 (No. 333-214013 and 333-177730), Form S-3ASR (No. 333-221501) and Form S-8 (No. 333-193340, 333-205057 and 333-220016) of Synergy Pharmaceuticals Inc. of our reports dated March 1, 2018, relating to the consolidated financial statements, and the effectiveness of Synergy Pharmaceuticals Inc.’s internal control over financial reporting, which appear in this Annual Report on Form 10-K. Our report on the financial statements contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.

/s/ BDO USA, LLP

New York, New York

March 1, 2018